Free Trial

Intellia Therapeutics (NTLA) Competitors

$21.73
-0.99 (-4.36%)
(As of 11:51 AM ET)

NTLA vs. CLDX, MYGN, QDEL, NEOG, EDIT, CRSP, CLLS, SGMO, LNTH, and JANX

Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), QuidelOrtho (QDEL), Neogen (NEOG), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Cellectis (CLLS), Sangamo Therapeutics (SGMO), Lantheus (LNTH), and Janux Therapeutics (JANX). These companies are all part of the "medical" sector.

Intellia Therapeutics vs.

Intellia Therapeutics (NASDAQ:NTLA) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.

Intellia Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

Celldex Therapeutics received 181 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 69.37% of users gave Intellia Therapeutics an outperform vote.

CompanyUnderperformOutperform
Intellia TherapeuticsOutperform Votes
419
69.37%
Underperform Votes
185
30.63%
Celldex TherapeuticsOutperform Votes
600
74.91%
Underperform Votes
201
25.09%

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 5 articles in the media. Celldex Therapeutics' average media sentiment score of 1.36 beat Intellia Therapeutics' score of 1.29 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Intellia Therapeutics has a net margin of -893.34% compared to Celldex Therapeutics' net margin of -2,385.57%. Celldex Therapeutics' return on equity of -29.55% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-893.34% -45.35% -37.40%
Celldex Therapeutics -2,385.57%-29.55%-27.66%

88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.0% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Intellia Therapeutics currently has a consensus price target of $66.77, suggesting a potential upside of 193.88%. Celldex Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 86.55%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69
Celldex Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Celldex Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$36.28M60.41-$481.19M-$5.36-4.24
Celldex Therapeutics$6.88M338.94-$141.43M-$2.85-12.41

Summary

Celldex Therapeutics beats Intellia Therapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NTLA vs. The Competition

MetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$2.19B$3.01B$5.00B$8.09B
Dividend YieldN/A0.69%2.74%3.96%
P/E Ratio-4.24157.16176.4818.43
Price / Sales60.4181.162,386.6172.31
Price / CashN/A18.6833.0728.77
Price / Book1.943.704.944.39
Net Income-$481.19M$36.23M$104.35M$213.55M
7 Day Performance-11.63%-1.75%-0.63%-0.80%
1 Month Performance9.44%2.60%3.85%3.42%
1 Year Performance-41.71%-27.37%5.47%7.53%

Intellia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLDX
Celldex Therapeutics
1.5291 of 5 stars
$37.67
-0.2%
$66.00
+75.2%
+15.7%$2.48B$6.88M-13.22160Short Interest ↓
News Coverage
Positive News
MYGN
Myriad Genetics
3.5139 of 5 stars
$24.38
-2.5%
$25.57
+4.9%
+4.6%$2.21B$753.20M-8.652,700Gap Down
QDEL
QuidelOrtho
4.2862 of 5 stars
$41.35
-2.5%
$59.00
+42.7%
-48.5%$2.77B$3.00B-1.577,100
NEOG
Neogen
3.4284 of 5 stars
$13.37
-2.2%
$22.50
+68.3%
-21.0%$2.90B$822.45M1,338.342,640News Coverage
Positive News
EDIT
Editas Medicine
3.7413 of 5 stars
$5.51
-0.2%
$13.90
+152.3%
-41.5%$453.14M$78.12M-2.62265
CRSP
CRISPR Therapeutics
2.2469 of 5 stars
$54.76
-1.3%
$73.93
+35.0%
-15.2%$4.65B$371.21M-20.13473Short Interest ↑
CLLS
Cellectis
3.0812 of 5 stars
$2.95
-0.7%
$8.50
+188.1%
+51.9%$163.96M$9.19M-1.72231Analyst Forecast
Short Interest ↓
News Coverage
Positive News
Gap Down
SGMO
Sangamo Therapeutics
1.6095 of 5 stars
$0.60
-3.2%
$5.67
+848.6%
-50.7%$123.97M$176.23M-0.32405Positive News
LNTH
Lantheus
4.2577 of 5 stars
$80.70
-2.6%
$99.17
+22.9%
-12.8%$5.59B$1.30B12.32834Positive News
JANX
Janux Therapeutics
3.5649 of 5 stars
$45.49
-5.2%
$69.50
+52.8%
+315.1%$2.49B$7.29M-37.2964Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:NTLA) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners